Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects ...

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in 2026 on Tuesday, banking on strong demand for cancer drugs and new launches ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. | AstraZeneca is ...

Feb 24 (Reuters) - AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) ...

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leu ...

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its oncology, ...

The drug maker’s annual report showed his total pay lifted 6.4% last year after he was awarded nearly £16 million in bonuses and share awards.

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...

The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

As the world went into lockdown a year ago, the workforce of AstraZeneca got news that some at the British-Swedish pharmaceutical giant considered deflating. With a global public health crisis raging ...